Metabolomic Mapping of Atypical Antipsychotic Effects in Schizophrenia
Abstract
Schizophrenia is associated with impairments in neurotransmitter systems and changes in neuronal membrane phospholipids. Several atypical antipsychotic drugs induce weight gain and hypertriglyceridemia. To date, there has not been a comprehensive evaluation and mapping of global lipid changes in schizophrenia, and upon treatment with antipsychotics. Such mapping could provide novel insights about disease mechanisms and metabolic side effects of therapies used for its treatment. We used a specialized metabolomics platform 'lipidomics' that quantifies over 300 polar and nonpolar lipid metabolites (across seven lipid classes) to evaluate global lipid changes in schizophrenia and upon treatment with three commonly used atypical antipsychotics. Lipid profiles were derived for 50 patients with schizophrenia before and after treatment for 2-3 weeks with olanzapine (n=20), risperidone (n=14) or aripiprazole (n=16). Patients were recruited in two cohorts (study I, n=27 and study II, n=23) to permit an internal replication analyses. The change from baseline to post-treatment was then compared among the three drugs. Olanzapine and risperidone affected a much broader range of lipid classes than aripiprazole. Approximately 50 lipids tended to be increased with both risperidone and olanzapine and concentrations of triacylglycerols increased and free fatty acids decreased with both drugs but not with aripiprazole. Phosphatidylethanolamine concentrations that were suppressed in patients with schizophrenia were raised by all three drugs. Drug specific differences were also detected. A principal component analysis (PCA) identified baseline lipid alterations, which correlated with acute treatment response. A more definitive long-term randomized study of these drugs correlating global lipid changes with clinical outcomes could yield biomarkers that define drug-response phenotypes.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Neuroleptic therapy affects lipid homeostasis.
“Among others, neuroleptic therapy affects lipid homeostasis [130,131].”
From Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers (2024) · cites this paper as [130]
Typical and atypical antipsychotics increase the levels of cholesterol, TG, and LDL.
“In particular, it was shown that typical and atypical antipsychotics increase the levels of cholesterol, TG, and LDL.”
From Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers (2024) · cites this paper as [130]
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,706 · see citing works
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189 · see citing works
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516 · see citing works
(1976) · Medical Entomology and Zoology · Cited by 8,899 · see citing works
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · see citing works
Psychopharmacology: The Third Generation of Progress.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-509_2 · Cited by 2,021 · see citing works
Jablensky, A., Sartorius, N., Ernberg, G., Anker, M., Korten, A., Cooper, J. E., Day, R., & Bertelsen, A. (1992) · Psychological Medicine. Monograph Supplement · doi:10.1017/s0264180100000904 · Cited by 1,769 · see citing works
Brindle, J. T., Antti, H., Holmes, E. C., Tranter, G. E., Nicholson, J. K., Bethell, H., Clarke, S., Schofield, P. M., McKilligin, E., Mosedale, D. E., et al. (2002) · Nature Medicine · doi:10.1038/nm1202-802 · Cited by 1,031 · see citing works
Prediction of Outcome in Schizophrenia
Strauss, J. S. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770140049005 · Cited by 522 · see citing works
Carpenter, W. T., & Buchanan, R. W. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403103301006 · Cited by 510 · see citing works
Schizophrenia : manifestations, incidence and course in different cultures
Zhablenski, A. V. (1992) · Cambridge University Press eBooks · Cited by 506 · see citing works
Pettegrew, J. W. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810300075011 · Cited by 482 · see citing works
Horrobin, D. F. (1998) · Schizophrenia Research · doi:10.1016/s0920-9964(97)00151-5 · Cited by 456 · see citing works
Watson, A. D. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600022-jlr200 · Cited by 455 · see citing works
Lindon, J. C., Holmes, E. C., Bollard, M. E., Stanley, E. G., & Nicholson, J. K. (2004) · Biomarkers · doi:10.1080/13547500410001668379 · Cited by 451 · see citing works
Metabolic Profiling: Its Role in Biomarker Discovery and Gene Function Analysis
(2003) · Springer eBooks · doi:10.1007/978-1-4615-0333-0 · Cited by 390 · see citing works
(2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0219 · Cited by 383 · see citing works
Detection of epithelial ovarian cancer using 1 H‐NMR‐based metabonomics
Odunsi, K. O., Wollman, R. M., Ambrosone, C. B., Hutson, A. D., McCann, S. E., Tammela, J., Geisler, J. P., Miller, G., Sellers, T. A., Cliby, W. A., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20651 · Cited by 319 · see citing works
Holmes, E. C., Tsang, T. M., Huang, J. T.-J., Leweke, F. M., Koethe, D., Gerth, C. W., Nolden, B. M., Gross, S., Schreiber, D., Nicholson, J. K., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030327 · Cited by 292 · see citing works
Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients
Yao, J. K., Leonard, S. S., & Reddy, R. D. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00095-x · Cited by 290 · see citing works
Psychopharmacologic Treatment of Schizophrenia
Kane, J. M., & Marder, S. R. (1993) · Schizophrenia Bulletin · doi:10.1093/schbul/19.2.287 · Cited by 275 · see citing works
Lipid metabolome-wide effects of the PPARγ agonist rosiglitazone
Watkins, S. M., Reifsnyder, P. C., Pan, H.-J., German, J. B., & Leiter, E. H. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200169-jlr200 · Cited by 274 · see citing works
Wang, C., Kong, H., Guan, Y., Yang, J., Gu, J., Yang, S., & Xu, G. (2005) · Analytical Chemistry · doi:10.1021/ac0481001 · Cited by 270 · see citing works
Warensjö, E., Öhrvall, M., & Vessby, B. O. (2005) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2005.06.001 · Cited by 255 · see citing works
McQuade, R. D., Stock, E. G., Marcus, R. N., Jody, D. N., Abou-Gharbia, N., Vanveggel, S., Archibald, D., & Carson, W. H. (2004) · PubMed · Cited by 244 · see citing works
Fatty acid levels in the brains of schizophrenics and normal controls
Horrobin, D. F., Manku, M. S., Hillman, H., IAIN, A., & Glen, M. (1991) · Biological Psychiatry · doi:10.1016/0006-3223(91)90235-e · Cited by 240 · see citing works
DIETARY LIPIDS AND POSTNATAL DEVELOPMENT
(1972) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1972.tb01447.x · Cited by 195 · see citing works
Brindle, J. T., Nicholson, J. K., Schofield, P. M., Grainger, D. J., & Holmes, E. C. (2002) · The Analyst · doi:10.1039/b209155k · Cited by 190 · see citing works
Fernø, J., Raeder, M. B., Vik‐Mo, A. O., Skrede, S., Glambek, M., Tronstad, K. J., Breilid, H., Løvlie, R., Berge, R. K., Stansberg, C. T., et al. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500323 · Cited by 152 · see citing works
Metabolomic analysis and signatures in motor neuron disease
Rozen, S., Cudkowicz, M., Bogdanov, M. B., Matson, W. R., Kristal, B. S., Beecher, C., Harrison, S. J., Vouros, P., Flarakos, J., Vigneau-Callahan, K. E., et al. (2005) · Metabolomics · doi:10.1007/s11306-005-4810-1 · Cited by 146 · see citing works
Prediction of outcome in schizophrenia
Jonsson, H., & Nyman, A. K. (1984) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1984.tb02497.x · Cited by 140 · see citing works
Biological Studies in Schizophrenia
Meltzer, H. Y. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.1.77 · Cited by 135 · see citing works
Novel biomarkers for pre-eclampsia detected using metabolomics and machine learning
Kenny, L. C., Dunn, W. B., Ellis, D. I., Myers, J., Baker, P. N., & Kell, D. B. (2005) · Metabolomics · doi:10.1007/s11306-005-0003-1 · Cited by 122 · see citing works
Schizophrenia as a membrane lipid disorder which is expressed throughout the body
Horrobin, D. F. (1996) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/s0952-3278(96)90138-6 · Cited by 113 · see citing works
Rosiglitazone Increases Indexes of Stearoyl-CoA Desaturase Activity in Humans
Risérus, U., Tan, G. D., Fielding, B. A., Neville, M. J., Currie, J. M., Savage, D. B., Chatterjee, K., Frayn, K. N., O’Rahilly, S., & Karpe, F. (2005) · Diabetes · doi:10.2337/diabetes.54.5.1379 · Cited by 109 · see citing works
Yao, J. K., Stanley, J. A., Reddy, R. D., Keshavan, M. S., & Pettegrew, J. W. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01397-5 · Cited by 100 · see citing works
Erythrocyte membrane phospholipids in psychotic patients
Keshavan, M. S., Mallinger, A. G., Pettegrew, J. W., & Dippold, C. S. (1993) · Psychiatry Research · doi:10.1016/0165-1781(93)90032-c · Cited by 95 · see citing works
Mahadik, S. P., Mukherjee, S., Correnti, E. E., Kelkar, H. S., Wakade, C. G., Costa, R. M., & Scheffer, R. E. (1994) · Schizophrenia Research · doi:10.1016/0920-9964(94)90048-5 · Cited by 82 · see citing works
Essential fatty acids in plasma phospholipids in schizophrenics
Horrobin, D. F., Manku, M. S., Fisher, N. M., Vaddadi, K. S., Courtney, P., Glen, A. I. M., Glen, E. M. T., Spellman, M., & Bates, C. (1989) · Biological Psychiatry · doi:10.1016/0006-3223(89)90216-3 · Cited by 78 · see citing works
Lutzke, B., & Braughler, J. M. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42278-3 · Cited by 75 · see citing works
Watkins, S. M., Lin, T. Y., Davis, R. M., Ching, J. R., DePeters, E. J., HALPERN, G. M., Walzem, R. L., & German, J. B. (2001) · Lipids · doi:10.1007/s11745-001-0714-8 · Cited by 69 · see citing works
Raeder, M. B., Fernø, J., Glambek, M., Stansberg, C. T., & Steen, V. M. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.10.096 · Cited by 67 · see citing works
Dunne, V. G., Bhattachayya, S., Besser, M., Rae, C. D., & Griffin, J. L. (2004) · NMR in Biomedicine · doi:10.1002/nbm.918 · Cited by 65 · see citing works
Red blood cell membrane dynamics in schizophrenia
Yao, J., & van Kammen, D. (1993) · Schizophrenia Research · doi:10.1016/0920-9964(93)90509-h · Cited by 57 · see citing works
Essential and other fatty acids in plasma in schizophrenics and normal individuals from Japan
Kaiya, H., Horrobin, D. F., Manku, M. S., & Fisher, N. M. (1991) · Biological Psychiatry · doi:10.1016/0006-3223(91)90291-s · Cited by 55 · see citing works
YAO, J. K., van Kammen, D. P., & Gurklis, J. A. (1994) · Schizophrenia Research · doi:10.1016/0920-9964(94)90046-9 · Cited by 54 · see citing works
Richardson, A. J., Allen, S. J., Hajnal, J. V., Cox, I. J., Easton, T., & Puri, B. K. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00211-1 · Cited by 44 · see citing works
Metabolic Profiling of Patients with Schizophrenia
Kaddurah-Daouk, R. F. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030363 · Cited by 43 · see citing works
Effects of antipsychotic treatment on membrane phospholipid metabolism in schizophrenia
Schmitt, A., Maras, A., Petroianu, G. A., Braus, D. F., Scheuer, L., & Gattaz, W. F. (2001) · Journal of Neural Transmission · doi:10.1007/s007020170026 · Cited by 34 · see citing works
Metabolic Investigation in Psychiatric Disorders
Yao, J. K., & Reddy, R. D. (2005) · Molecular Neurobiology · doi:10.1385/mn:31:1-3:193 · Cited by 33 · see citing works
Shiwaku, K., Hashimoto, M., Kitajima, K., Nogi, A., Anuurad, E., Enkhmaa, B., Kim, J.-M., Kim, I., Lee, S., Oyunsuren, T., et al. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m300483-jlr200 · Cited by 31 · see citing works
Lipomic profiling in drug discovery, development and clinical trial evaluation.
Watkins, S. M. (2004) · PubMed · Cited by 18 · see citing works
Mechanisms of Action of Medicines for Schizophrenia and Bipolar Illness: Status and Limitations
Scolnick, E. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.022 · Cited by 12 · see citing works
Flagged first, then by citations
1 of the 54 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Correll, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050 · see citing works
Metabolomics: A Global Biochemical Approach to Drug Response and Disease
Kaddurah-Daouk, R. F., Kristal, B. S., & Weinshilboum, R. M. (2008) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094715 · Cited by 669 · see citing works
Metabolomics enables precision medicine: “A White Paper, Community Perspective”
for “Precision Medicine and Pharmacometabolomics Task Group”-Metabolomics Society Initiative, Beger, R. D., Dunn, W., Schmidt, M. A., Gross, S. S., Kirwan, J. A., Cascante, M., Brennan, L., Wishart, D. S., Oresic, M., et al. (2016) · Metabolomics · doi:10.1007/s11306-016-1094-6 · Cited by 592 · see citing works
Chemometrics in metabolomics—A review in human disease diagnosis
Madsen, R., Lundstedt, T., & Trygg, J. (2009) · Analytica Chimica Acta · doi:10.1016/j.aca.2009.11.042 · Cited by 559 · see citing works
Andreassen, O. A., Djurovic, S., Thompson, W. K., Schork, A. J., Kendler, K. S., O’Donovan, M. C., Rujescu, D., Werge, T., van de Bunt, M., Morris, A. P., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.01.001 · Cited by 506 · see citing works
Han, X., Rozen, S., Boyle, S. H., Hellegers, C., Cheng, H., Burke, J. R., Welsh-Bohmer, K. A., Doraiswamy, P. M., & Kaddurah-Daouk, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021643 · Cited by 429 · see citing works
Personalized Medicine: Progress and Promise
Chan, I. S., & Ginsburg, G. S. (2011) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082410-101446 · Cited by 399 · see citing works
Systems Pharmacology: Network Analysis to Identify Multiscale Mechanisms of Drug Action
Zhao, S., & Iyengar, R. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134520 · Cited by 358 · see citing works
NMR-based metabolomics in human disease diagnosis: applications, limitations, and recommendations
Emwas, A.-H. M., Salek, R. M., Griffin, J. L., & Merzaban, J. S. (2013) · Metabolomics · doi:10.1007/s11306-013-0524-y · Cited by 296 · see citing works
Metabolomics: A Global Biochemical Approach to the Study of Central Nervous System Diseases
Kaddurah-Daouk, R. F., & Krishnan, K. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.174 · Cited by 289 · see citing works
Current metabolomics: Practical applications
Putri, S. P., Nakayama, Y., Matsuda, F., Uchikata, T., Kobayashi, S., Matsubara, A., & Fukusaki, E. (2013) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2012.12.007 · Cited by 291 · see citing works
Metabolomics tools for identifying biomarkers for neuropsychiatric diseases
Quinones, M. P., & Kaddurah-Daouk, R. F. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.02.019 · Cited by 285 · see citing works
Inflammation and the two-hit hypothesis of schizophrenia
Feigenson, K. A., Kusnecov, A., & Silverstein, S. M. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.11.006 · Cited by 280 · see citing works
Potential metabolite markers of schizophrenia
Yang, J., Chen, T., Sun, L., Zhao, Z., Qi, X., Zhou, K., Cao, Y., Wang, X., Qiu, Y., Su, M., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.131 · Cited by 251 · see citing works
Applications of Metabolomics in Drug Discovery and Development
Wishart, D. S. (2008) · Drugs in R&D · doi:10.2165/00126839-200809050-00002 · Cited by 246 · see citing works
Liu, J. J., Green, P., Mann, J. J., Rapoport, S. I., & Sublette, M. E. (2014) · Brain Research · doi:10.1016/j.brainres.2014.11.059 · Cited by 234 · see citing works
Schwarz, E., Prabakaran, S., Whitfield, P. D., Major, H. J., Leweke, F. M., Koethe, D., McKenna, P. J., & Bahn, S. (2008) · Journal of Proteome Research · doi:10.1021/pr800188y · Cited by 222 · see citing works
An Efficient Single Phase Method for the Extraction of Plasma Lipids
Alshehry, Z. H., Barlow, C. K., Weir, J. M., Zhou, Y., McConville, M. J., & Meikle, P. J. (2015) · Metabolites · doi:10.3390/metabo5020389 · Cited by 219 · see citing works
Metabolomics for the masses: The future of metabolomics in a personalized world
Trivedi, D. K., Hollywood, K. A., & Goodacre, R. (2017) · European Journal of Molecular & Clinical Medicine · doi:10.1016/j.nhtm.2017.06.001 · Cited by 193 · see citing works
Pharmacometabolomics: Implications for Clinical Pharmacology and Systems Pharmacology
Kaddurah-Daouk, R. F., & Weinshilboum, R. M. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.217 · Cited by 190 · see citing works
Lipidomics: a new window to biomedical frontiers
Orešič, M., Hänninen, V. A., & Vidal‐Puig, A. (2008) · Trends in biotechnology · doi:10.1016/j.tibtech.2008.09.001 · Cited by 188 · see citing works
Cerebrospinal fluid metabolomics identifies 19 brain-related phenotype associations
Panyard, D. J., Kim, K. M., Darst, B. F., Deming, Y. K., Zhong, X., Wu, Y., Kang, H., Carlsson, C. M., Johnson, S. C., Asthana, S., et al. (2021) · Communications Biology · doi:10.1038/s42003-020-01583-z · Cited by 179 · see citing works
How can we realize the promise of personalized antidepressant medicines?
Holsboer, F. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2453 · Cited by 177 · see citing works
Schizophrenia shows a unique metabolomics signature in plasma
He, Y., Yu, Z., Giegling, I., Xie, L., Hartmann, A. M., Prehn, C. P., Adamski, J., Kahn, R. S., Li, Y., Illig, T., et al. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.76 · Cited by 170 · see citing works
Orešič, M., Seppänen‐Laakso, T., Sun, D., Tang, J. P., Therman, S., Viehman, R., Mustonen, U., van Erp, T. G., Hyötyläinen, T., Thompson, P. M., et al. (2012) · eScholarship (California Digital Library) · Cited by 168 · see citing works
A systematic review of metabolite biomarkers of schizophrenia
Davison, J., O’Gorman, A., Brennan, L., & Cotter, D. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.09.021 · Cited by 161 · see citing works
Metabolomics: Moving to the Clinic
Nordström, A., & Lewensohn, R. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9156-4 · Cited by 164 · see citing works
Metabolomics, a novel tool for studies of nutrition, metabolism and lipid dysfunction
Orešič, M. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.04.018 · Cited by 163 · see citing works
Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine
Kaddurah-Daouk, R. F., & Weinshilboum, R. M. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.134 · Cited by 162 · see citing works
Ji, Y., Hebbring, S. J., Zhu, H., Jenkins, G. D., Biernacka, J. M., Snyder, K., Drews, M., Fiehn, O., Zeng, Z., Schaid, D. J., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.250 · Cited by 160 · see citing works
Metabolome in schizophrenia and other psychotic disorders: a general population-based study
Orešič, M., Tang, J. P., Seppänen‐Laakso, T., Mattila, I. M., Saarni, S. E., Saarni, S. I., Lönnqvist, J. K., Sysi‐Aho, M., Hyötyläinen, T., Perälä, J., et al. (2011) · Genome Medicine · doi:10.1186/gm233 · Cited by 158 · see citing works
Metabolomic changes in autopsy‐confirmed Alzheimer's disease
Kaddurah-Daouk, R. F., Rozen, S., Matson, W. R., Han, X., Hulette, C. M., Burke, J. R., Doraiswamy, P. M., & Welsh-Bohmer, K. A. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.06.001 · Cited by 145 · see citing works
Lipidome alterations in human prefrontal cortex during development, aging, and cognitive disorders
Yu, Q., He, Z., Zubkov, D., Huang, S., Kurochkin, I., Yang, X., Halene, T. B., Willmitzer, L., Giavalisco, P., Akbarian, S., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0200-8 · Cited by 131 · see citing works
Tsuruoka, M., Hara, J., Hirayama, A., Sugimoto, M., Soga, T., Shankle, W. R., & Tomita, M. (2013) · Electrophoresis · doi:10.1002/elps.201300019 · Cited by 130 · see citing works
Kaddurah-Daouk, R. F., Boyle, S. H., Matson, W. R., Sharma, S., Matson, S. A., Zhu, H., Bogdanov, M. B., Churchill, E., Krishnan, R. R., Rush, A. J., et al. (2011) · Translational Psychiatry · doi:10.1038/tp.2011.22 · Cited by 129 · see citing works
McEvoy, J., Baillie, R. A., Zhu, H., Buckley, P., Keshavan, M. S., Nasrallah, H. A., Dougherty, G. G., Yao, J. K., & Kaddurah-Daouk, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068717 · Cited by 127 · see citing works
Altmaier, E., Ramsay, S. L., Graber, A., Mewes, H., Weinberger, K. M., & Suhre, K. (2008) · Endocrinology · doi:10.1210/en.2007-1747 · Cited by 124 · see citing works
Omics-Based Biomarkers: Application of Metabolomics in Neuropsychiatric Disorders
Sethi, S., & Brietzke, E. M. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv096 · Cited by 122 · see citing works
Albaugh, V. L., Singareddy, R. K., Mauger, D., & Lynch, C. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022662 · Cited by 119 · see citing works
Yao, J., Dougherty, G. G., Reddy, R. D., Keshavan, M. S., Montrose, D. M., Matson, W. R., Rozen, S., Krishnan, R. R., McEvoy, J. P., & Kaddurah-Daouk, R. F. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.33 · Cited by 118 · see citing works
Cai, H., Huan-de, L., Yan, X., Sun, B. H., Zhang, Q., Yan, M., Zhang, W., Jiang, P., Zhu, R., Liu, Y., et al. (2012) · Journal of Proteome Research · doi:10.1021/pr300459d · Cited by 115 · see citing works
Albaugh, V. L., Judson, J., She, P., Lang, C. H., Maresca, K. P., Joyal, J. L., & Lynch, C. J. (2010) · Molecular Psychiatry · doi:10.1038/mp.2010.33 · Cited by 114 · see citing works
Fernø, J., Vik‐Mo, A. O., Jassim, G., Håvik, B., Berge, K., Skrede, S., Gudbrandsen, O. A., Waage, J. E. R., Lunder, N., Mørk, S. J., et al. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1370-x · Cited by 104 · see citing works
Biomarker Discovery and Translation in Metabolomics
Gowda, G. N., & Raftery, D. (2013) · Current Metabolomics · doi:10.2174/2213235x113019990005 · Cited by 102 · see citing works
Current Concepts in Pharmacometabolomics, Biomarker Discovery, and Precision Medicine
Beger, R. D., Schmidt, M. A., & Kaddurah-Daouk, R. F. (2020) · Metabolites · doi:10.3390/metabo10040129 · Cited by 103 · see citing works
Alcohol-induced metabolomic differences in humans
Jaremek, M., Yu, Z., Mangino, M., Mittelstraß, K., Prehn, C. P., Singmann, P., Xu, T., Dahmen, N., Weinberger, K. M., Suhre, K., et al. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.55 · Cited by 100 · see citing works
Metabolomics and Detection of Colorectal Cancer in Humans: A Systematic Review
Wang, H., Tso, V., Slupsky, C. M., & Fedorak, R. N. (2010) · Future Oncology · doi:10.2217/fon.10.107 · Cited by 100 · see citing works
Condray, R., Dougherty, G. G., Keshavan, M. S., Reddy, R. D., Haas, G. L., Montrose, D. M., Matson, W. R., McEvoy, J. P., Kaddurah-Daouk, R. F., & Yao, J. K. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001689 · Cited by 98 · see citing works
Kantae, V., Krekels, E. H. J., van Esdonk, M. J., Lindenburg, P. W., Harms, A. C., Knibbe, C. A. J., van der Graaf, P. H., & Hankemeier, T. (2016) · Metabolomics · doi:10.1007/s11306-016-1143-1 · Cited by 97 · see citing works
Rotroff, D. M., Corum, D. G., Motsinger‐Reif, A. A., Fiehn, O., Bottrel, N., Drevets, W. C., Singh, J. B., Salvadore, G., & Kaddurah‐Daouk, R. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.145 · Cited by 95 · see citing works
Metabolomics In Biomarker Discovery: Future Uses For Cancer Prevention
Kim, Y. S., Maruvada, P., & Milner, J. A. (2008) · Future Oncology · doi:10.2217/14796694.4.1.93 · Cited by 93 · see citing works
Alterations in tryptophan and purine metabolism in cocaine addiction: a metabolomic study
Patkar, A. A., Rozen, S., Mannelli, P., Matson, W. R., Pae, C., Krishnan, K., & Kaddurah-Daouk, R. F. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1625-1 · Cited by 91 · see citing works
Effects of Olanzapine and Haloperidol on the Metabolic Status of Healthy Men
Vidarsdóttir, S., van Weenen, J. E. D. L., Frölich, M., Roelfsema, F., Romijn, J. A., & Pijl, H. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1815 · Cited by 91 · see citing works
Metabolomic analysis of male combat veterans with post traumatic stress disorder
Mellon, S. H., Bersani, F. S., Lindqvist, D., Hammamieh, R., Donohue, D., Dean, K., Jett, M., Yehuda, R., Flory, J., Reus, V. I., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0213839 · Cited by 85 · see citing works
Impaired Plasmalogens in Patients with Schizophrenia
Kaddurah-Daouk, R., McEvoy, J., Baillie, R., Zhu, H., K. Yao, J., Nimgaonkar, V. L., Buckley, P. F., Keshavan, M. S., Georgiades, A., & Nasrallah, H. A. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.02.019 · Cited by 89 · see citing works
Self-citationCryptides: Buried secrets in proteins
Pimenta, D. C., & Lebrun, I. (2007) · Peptides · doi:10.1016/j.peptides.2007.10.005 · Cited by 87 · see citing works
Albaugh, V. L., Vary, T. C., Ilkayeva, O., Wenner, B. R., Maresca, K. P., Joyal, J. L., Breazeale, S. D., Elich, T. D., Lang, C. H., & Lynch, C. J. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq053 · Cited by 86 · see citing works
Lipidomics in the study of lipid metabolism: Current perspectives in the omic sciences
Rolim, A. E. H., Henrique-Araújo, R., Ferraz, E. G., Dultra, F. K. A. A., & Fernandez, L. G. (2014) · Gene · doi:10.1016/j.gene.2014.10.039 · Cited by 85 · see citing works
Polymeropoulos, M. H., Licamele, L., Volpi, S., Mack, K., Mitkus, S. N., Carstea, E. D., Getoor, L. C., Thompson, A. D., & Lavedan, C. N. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.11.025 · Cited by 83 · see citing works
Systems biology strategies to study lipidomes in health and disease
Hyötyläinen, T., & Orešič, M. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2014.06.001 · Cited by 82 · see citing works
Skrede, S., Fernø, J., Vazquez, M. J., Fjær, S., Pavlin, T., Lunder, N., Vidal‐Puig, A., Diéguez, C., Berge, R. K., López, M., et al. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001271 · Cited by 80 · see citing works
Cerebrospinal Fluid Metabolome in Mood Disorders-Remission State has a Unique Metabolic Profile
Kaddurah-Daouk, R., Yuan, P., Boyle, S. H., Matson, W., Wang, Z., Zeng, Z. B., Zhu, H., Dougherty, G. G., Yao, J. K., Chen, G., et al. (2012) · Scientific Reports · doi:10.1038/srep00667 · Cited by 76 · see citing works
Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients
Bhattacharyya, S., Ahmed, A. T., Arnold, M., Liu, D., Luo, C., Zhu, H., MahmoudianDehkordi, S., Neavin, D. R., Louie, G., Dunlop, B. W., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0507-5 · Cited by 78 · see citing works
Pharmacometabonomics and personalized medicine
Everett, J. R., Loo, R. L., & Pullen, F. S. (2013) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563213497929 · Cited by 75 · see citing works
Identification of biomarkers to diagnose diseases and find adverse drug reactions by metabolomics
Saigusa, D., Matsukawa, N., Hishinuma, E., & Koshiba, S. (2020) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2020.11.008 · Cited by 75 · see citing works
Metabolic Profiling Identifies Phospholipids as Potential Serum Biomarkers for Schizophrenia
Wang, D., Cheng, S. L., Fei, Q., Gu, H., Raftery, D., Cao, B., Sun, X., Yan, J., Zhang, C., & Wang, J. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2018.12.008 · Cited by 73 · see citing works
Metabolomic Differences in Heart Failure Patients With and Without Major Depression
Steffens, D. C., Jiang, W., Krishnan, K. R. R., Karoly, E. D., Mitchell, M. W., O'Connor, C. M., & Kaddurah-Daouk, R. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988709358592 · Cited by 68 · see citing works
Pharmacogenomics: a systems approach
Wang, L. (2009) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.42 · Cited by 68 · see citing works
Vik‐Mo, A. O., Birkenaes, A. B., Fernø, J., Jónsdóttir, H., Andreassen, O. A., & Steen, V. M. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708008468 · Cited by 68 · see citing works
Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism
Teff, K. L., & Kim, S. F. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.05.033 · Cited by 67 · see citing works
Opioid use affects antioxidant activity and purine metabolism: preliminary results
Mannelli, P., Patkar, A. A., Rozen, S., Matson, W. R., Krishnan, R. R., & Kaddurah-Daouk, R. F. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1068 · Cited by 66 · see citing works
Kristiana, I., Sharpe, L. J., Catts, V. S., Lutze-Mann, L. H., & Brown, A. J. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.62 · Cited by 64 · see citing works
Liu, J., Litt, L. L., Segal, M. R., Kelly, M. J. S., Pelton, J. G., & Kim, M. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12106469 · Cited by 62 · see citing works
Schizophrenia: A review of potential biomarkers
Rodrígues-Amorím, D., Baltanás, T. R., López, M., Spuch, C., Olivares, J. M., & Agís‐Balboa, R. C. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.05.009 · Cited by 62 · see citing works
From Metabonomics to Pharmacometabonomics: The Role of Metabolic Profiling in Personalized Medicine
Everett, J. R. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00297 · Cited by 60 · see citing works
Lipidomes in health and disease: Analytical strategies and considerations
Wei, F., Lamichhane, S., Orešič, M., & Hyötyläinen, T. (2019) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2019.115664 · Cited by 60 · see citing works
Fan, T. W. ‐., Yuan, P., Lane, A. N., Higashi, R. M., Wang, Y., Hamidi, A., Zhou, R., Guitart, X., Chen, G., Manji, H. K., et al. (2010) · Metabolomics · doi:10.1007/s11306-010-0208-9 · Cited by 57 · see citing works
Metabolomic profiling of schizophrenia patients at risk for metabolic syndrome
Paredes, R. M., Quinones, M. P., Marballi, K. K., Gao, X., Valdez, C., Ahuja, S. S., Velligan, D. I., & Walss‐Bass, C. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000157 · Cited by 57 · see citing works
Panenka, W. J., Lange, R. T., Sylvain Bouix, A., Shewchuk, J. R., Heran, M. K. S., Brubacher, J. R., Eckbo, R., Shenton, M. E., & Iverson, G. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122746 · Cited by 54 · see citing works
Motsinger‐Reif, A. A., Zhu, H., Kling, M. A., Matson, W. R., Sharma, S., Fiehn, O., Reif, D. M., Appleby, D. H., Doraiswamy, P. M., Trojanowski, J. Q., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-28 · Cited by 54 · see citing works
Antipsychotics Promote Metabolic Disorders Disrupting Cellular Lipid Metabolism and Trafficking
Vantaggiato, C., Panzeri, E., Citterio, A., Orso, G., & Pozzi, M. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.01.003 · Cited by 53 · see citing works
Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry
Lozupone, M., Seripa, D., Stella, E., Montagna, M. L., Solfrizzi, V., Quaranta, N. A. A., Veneziani, F., Cester, A., Sardone, R., Bonfiglio, C., et al. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1375857 · Cited by 51 · see citing works
Dysfunctional plasmalogen dynamics in the plasma and platelets of patients with schizophrenia
Wood, P. L., Unfried, G., Whitehead, W. F., Phillipps, A., & Wood, J. A. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.11.032 · Cited by 50 · see citing works
Kale, A. A., Joshi, S., Naphade, N. M., Sapkale, S., Raju, M. S. V. K., Pillai, A., Nasrallah, H. A., & Mahadik, S. P. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.09.036 · Cited by 50 · see citing works
Impaired Metabolic Reactivity to Oxidative Stress in Early Psychosis Patients
Fournier, M., Ferrari, C., Baumann, P. S., Polari, A., Monin, A., Bellier-Teichmann, T., Wulff, J., Pappan, K. L., Cuenod, M., Conus, P., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu053 · Cited by 48 · see citing works
Cheon, Y., Park, J., Modi, H. R., Kim, H., Lee, H., Chang, L., Rao, J. S., & Rapoport, S. I. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07410.x · Cited by 50 · see citing works
Webhofer, C., Gormanns, P., Tolstikov, V., Zieglgänsberger, W., Sillaber, I., Holsboer, F., & Turck, C. W. (2011) · Translational Psychiatry · doi:10.1038/tp.2011.56 · Cited by 48 · see citing works
Solberg, D. K., Bentsen, H., Refsum, H., & Andreassen, O. A. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12388 · Cited by 47 · see citing works
Profiling of Acylcarnitines in First Episode Psychosis before and after Antipsychotic Treatment
Kriisa, K., Leppik, L., Balõtšev, R., Ottas, A., Soomets, U., Koido, K., Volke, V., Innos, J., Haring, L., Vasar, E., et al. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00279 · Cited by 47 · see citing works
Kroken, R. A., Løberg, E., Drønen, T., Grüner, R., Hugdahl, K., Kompus, K., Skrede, S., & Johnsen, E. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00011 · Cited by 46 · see citing works
Understanding human metabolic physiology: a genome-to-systems approach
Mo, M. L., & Palsson, B. Ø. (2008) · Trends in biotechnology · doi:10.1016/j.tibtech.2008.09.007 · Cited by 46 · see citing works
Steen, V. M., Skrede, S., Polushina, T. V., López, M., Andreassen, O. A., Fernø, J., & Hellard, S. L. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.07.011 · Cited by 47 · see citing works
Dumas, M., & Davidovic, L. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-014-9578-5 · Cited by 46 · see citing works
Liu, Y., Jandacek, R. J., Rider, T., Tso, P., & McNamara, R. K. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.12.027 · Cited by 46 · see citing works
van Beveren, N. J. M., Schwarz, E., Noll, R., Guest, P. C., Meijer, C. J., de Haan, L., & Bahn, S. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.52 · Cited by 45 · see citing works
Analytical approaches for lipidomics and its potential applications in neuropsychiatric disorders
Sethi, S., Hayashi, M. A. F., Sussulini, A., Tasić, L., & Brietzke, E. M. (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1117656 · Cited by 44 · see citing works
Nam, H. W., Karpyak, V. M., Hinton, D. J., Geske, J. R., Ho, A. M., Prieto, M. L., Biernacka, J. M., Frye, M. A., Weinshilboum, R. M., & Choi, D.-S. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.120 · Cited by 44 · see citing works
Biomarkers for Psychiatric Disorders
Turck, C. W. (2009) · Springer eBooks · doi:10.1007/978-0-387-79251-4 · Cited by 42 · see citing works
Tasić, L., Pontes, J. G. M., Carvalho, M. S., Cruz, G. C. F., Mas, C. D., Sethi, S., Pedrini, M., Rizzo, L., Zeni-Graiff, M., Asevedo, E., et al. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2016.12.024 · Cited by 39 · see citing works
Klingerman, C. M., Stipanovic, M. E., Bader, M., & Lynch, C. J. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs196 · Cited by 42 · see citing works
- Authors
- Kaddurah-Daouk, R., McEvoy, J., Baillie, R. A., Lee, D., Yao, J. K., Doraiswamy, P. M., & Krishnan, K. R. R.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- University of Pittsburgh (US)
- Corresponding author
- Kaddurah-Daouk, R
- Venue
- Molecular Psychiatry
- Published
- 2007-04-17
- Volume
- 12
- Issue
- 10
- Pages
- 934-945
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W1987857702
- Cited by
- 262
- References
- 54
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 11 · 2023: 12 · 2022: 11 · 2021: 11 · 2020: 13 · 2019: 10 · 2018: 10 · 2017: 9 · 2016: 20 · 2015: 14 · 2014: 15 · 2013: 19 · 2012: 18
- FWCI
- 11.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- schizophrenia, atypical antipsychotics, lipidomics, lipid metabolism, olanzapine, risperidone, aripiprazole, triglycerides, free fatty acids, phosphatidylethanolamine, treatment response biomarkers
- MeSH terms
- Adult, Analysis of Variance, Female, Humans, Lipids, Male, Psychiatric Status Rating Scales, Schizophrenia, Antipsychotic Agents, Cohort Studies, Principal Component Analysis, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
